Search Results
Your search for The A matches 31882 pages
Showing 4201 - 4250Prolonging Remission in Anti–PD-1 Refractory Melanoma With Tumor-Infiltrating Lymphocyte Therapy
For the first time in a multicenter randomized trial, T-cell therapy has been shown to improve outcomes in a solid tumor. In the phase III M14TIL trial, first-line or second-line treatment with tumor-infiltrating lymphocytes (TIL) led to a 50% reduction in disease progression or death from advanced ...
UChicago Medicine Names New Associate Director of Cancer Prevention and Population Sciences
Jasmin A. Tiro, PhD, MPH, has joined the University of Chicago Medicine Comprehensive Cancer Center as the new Associate Director of Cancer Prevention and Population Sciences. Dr. Tiro was formerly Professor of Population and Data Sciences at Harold C. Simmons Comprehensive Cancer Center at The...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Erica Huelsmann, MD, Wins a Conquer Cancer Annual Meeting Merit Award
Erica Huelsmann, MD, a gynecologic oncology fellow at Fox Chase Cancer Center, Philadelphia, has been awarded a 2022 Conquer Cancer Merit Award by Conquer Cancer, the ASCO Foundation. The award, given at the 2022 ASCO Annual Meeting, supports researchers with projects that span many areas of...
I’ve Had Two Primary Lung Cancers, and They Haven’t Defeated Me
I don’t know why I am so susceptible to developing lung cancer. Since 2014, I have been diagnosed with both non–small cell lung cancer (NSCLC) and small cell lung cancer, each occurring in my right lung. I have also been diagnosed with precancerous colon polyps, which necessitated invasive surgery. ...
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain...
HPV Vaccine ‘Works Astonishingly Well’
The human papillomavirus (HPV) vaccine “works astonishingly well. It really prevents the kind of infections that cause cancer,” commented Ruanne Barnabas, MBChB, MSc, DPhil, MD, PhD, in an interview with The ASCO Post. “Other viral infections are difficult to protect against, or there might be...
ECHELON-1 Shows Benefit for First-Line Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma
The results of ECHELON-1 were presented by David J. Straus, MD, of Memorial Sloan Kettering Cancer Center, New York, at the 2022 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies. Dr. Straus said: “It is a great honor and privilege to present updated results...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
The Evolving Role of PI3K Inhibitors in Double-Refractory CLL
The treatment paradigm for chronic lymphocytic leukemia (CLL) continues to evolve in the first-line setting and beyond, with the availability of Bruton’s tyrosine kinase (BTK) inhibitors, the BCL2 inhibitor venetoclax, and novel combinations of these agents with anti-CD20 monoclonal antibodies....
NCI Honors Augusto Ochoa, MD, for Contributions to Community-Based Cancer Clinical Trials
The National Cancer Institute (NCI) chose Augusto Ochoa, MD, of Louisiana State University (LSU) Health, as the 2022 recipient of the Harry Hynes Award for Outstanding Contributions to Clinical Trials and Community Research. The award was presented during the NCI Community Oncology Research Program ...
With Newer Therapies, AML Diagnosis and Prognosis Evolve
For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic targets makes discussions about treatment of this disease much more complicated. In fact, these...
Lutetium Lu-177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...
High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL
Which is the preferred second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): high-dose chemotherapy and autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T-cell therapy? This was the subject of a debate at the...
Pediatric Surgeon Henri R. Ford, MD, Chosen New President-Elect of American College of Surgeons
Pediatric surgeon and surgeon-scientist Henri R. Ford, MD, MHA, FACS, FRCS, FAAP, has been chosen as President-Elect of the American College of Surgeons during the organization’s recent annual business meeting of members. The First Vice-President-Elect, Tyler G. Hughes, MD, FACS, and Second...
New Directions for Cancer Care: Major Trends in U.S. Health Policy
The pace of cancer drug development may have accelerated over the past decade, but so too has the cost of care, which threatens to limit access for a large percentage of Americans in the decade to come. During the keynote lecture at the 2022 ASCO Quality Care Symposium, Ezekiel J. Emanuel, MD, PhD, ...
Integrative Approaches to Managing Pain in Patients With Cancer: SIO-ASCO Guideline
Pain is highly prevalent in people with cancer throughout the disease trajectory. Often persisting for years after initial diagnosis and undertreated, it is associated with poor functional, mental, and cancer-related outcomes.1 Consequently, the need for effective pain management strategies has...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?
The KRAS G12C inhibitor sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of disease progression or death by 34% compared with standard second-line docetaxel for patients with previously treated non–small cell lung cancer (NSCLC) and KRAS G12C mutations....
Study Finds Nearly Half of Black Women With Metastatic Breast Cancer Never Receive Information About Clinical Trial Participation
When Stephanie L. Walker, RN, was diagnosed with metastatic breast cancer in 2015, she was not given information about an appropriate clinical trial or help navigating her way through the financial difficulties she was having after a stroke from complications of the cancer forced her to leave her...
How to Advance Antiracist Approaches to Patient Engagement in AYA Oncology and Research
Among the topics discussed at the 4th Global Adolescent and Young Adult Cancer Congress held online in December 2021 was the urgent need for clinicians, researchers, and advocates in adolescent and young adult (AYA) oncology to join forces to eradicate racist approaches to patient engagement in...
Newly Diagnosed AML: Induction to Maintenance
When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...
‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs
As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...
Shorter Course of Hypofractionated Radiation Therapy Yields Comparable Results to Conventional Radiotherapy for Patients With Nonmetastatic Soft-Tissue Sarcoma
Patients with nonmetastatic soft-tissue sarcoma who need preoperative radiation therapy can safely receive hypofractionated treatment for 3 weeks instead of 5 weeks, with comparable tumor control and no increased risk of major complications in wound healing, according to a new study published by...
Some Head and Neck Cancer Survivors May Be at Greater Risk for Long-Term Gastrostomy Tube Use
A small subset of patients who have undergone treatment for head and neck cancer may require a gastrostomy tube many years into survivorship, according to a new study published by Galloway et al in the International Journal of Radiation Oncology, Biology, and Physics. The findings were also...
Addition of Brentuximab Vedotin to Chemotherapy in Pediatric High-Risk Hodgkin Lymphoma
As reported in The New England Journal of Medicine by Castellino et al, the phase III Children’s Oncology Group (COG) AHOD1331 trial showed improved event-free survival with brentuximab vedotin plus chemotherapy vs standard chemotherapy in previously untreated pediatric patients with high-risk...
Association of FLT3-ITD Measurable Residual Disease With Outcomes in Newly Diagnosed AML
In a study reported in the Journal of Clinical Oncology, Grob et al found that next-generation sequencing detection of FLT3-internal tandem duplication (FLT3-ITD) measurable residual disease (MRD) in complete remission was associated with markedly increased risk of relapse and poorer overall...
Effect of Smartphone Psychotherapy Apps on Fear of Recurrence Among Young Breast Cancer Survivors
In a Japanese trial (J-SUPPORT 1703) reported in the Journal of Clinical Oncology, Akechi et al found that 8-week use of smartphone psychotherapy apps was associated with significant benefits in reducing the fear of recurrence in breast cancer survivors aged 20 to 49 years. Study Details In the...
FDA Approves Cemiplimab-rwlc in Combination With Platinum-Based Chemotherapy for NSCLC
On November 8, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy for adult patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations. Study 16113 Efficacy was...
NCI-MATCH Trial: Ipatasertib Shows Signs of Effectiveness in Patients With AKT1 E17K–Mutant Solid Tumors
In the NCI-MATCH trial, which matches new treatments to patients with cancer based on the genetic makeup of their tumors, 22% of patients with AKT1 E17K–mutant metastatic tumors treated with the AKT inhibitor ipatasertib saw their tumors shrink, according to a novel study published by Kalinksy et...
Phase I Trial Shows Experimental Mini-Protein May Be Able to Inhibit the Cancer-Driving MYC Gene
Researchers have found that a new drug may be able to target—and for the first time, inhibit—the function of the MYC gene. Until now, no other drug has been able to do this safely and effectively, according to findings from a phase I clinical trial published by Garralda et al in the European...
Indian Trial Explores Addition of Low-Dose Nivolumab to Chemotherapy in Advanced Head and Neck Cancer
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Vijay Patil, MBBS, MD, DM, and colleagues found that the addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival in patients with newly diagnosed or recurrent...
Sequencing of Short-Duration ADT With Radiotherapy in Nonmetastatic Prostate Cancer
In a pooled analysis (SANDSTORM) reported in the Journal of Clinical Oncology, Ma et al found that concurrent/adjuvant short-term androgen-deprivation therapy (ADT) with prostate-only radiotherapy (PORT) was associated with better outcomes in multiple measures vs neoadjuvant/concurrent ADT with...
PET-Adapted Therapy for Bulky Stage I/II Classical Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Ann S. LaCasce, MD, MMSc, and colleagues, the phase II CALGB 50801/Alliance trial has shown that a positron-emission tomography (PET)-adapted treatment strategy allowed many patients with bulky stage I/II classical Hodgkin lymphoma to avoid...
Avoidance of Surgery in Patients With Invasive Breast Cancer and Exceptional Response to Neoadjuvant Systemic Therapy
In a phase II trial reported in The Lancet Oncology, Henry Kuerer, MD, PhD, FACS, and colleagues found radiotherapy alone among women with triple-negative or HER2-positive invasive breast cancer who had pathologic complete response on percutaneous image-guided, vacuum-assisted core biopsy (VACB)...
Repotrectinib for ROS1-Positive NSCLC Examined in Phase I/II TRIDENT-1 Trial
Early trials of the targeted oral drug repotrectinib discovered that it may help treat patients with a certain type of non–small cell lung cancer (NSCLC), according to a new study published by Cho et al in the European Journal of Cancer. The results of the TRIDENT-1 trial—presented at the 34th...
Preliminary Results From ARROS-1 Phase I Clinical Trial Suggest That NVL-520 May Be Well Tolerated and Active in NSCLC
Preliminary data from a phase I clinical trial of the ROS1 inhibitor NVL-520 to treat patients with non–small cell lung cancer (NSCLC) and other solid tumors suggested that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change and reach cancer cells within...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Mosaic Chromosomal Alterations and Risk of Lung Cancer
In a study reported in The Lancet Oncology, Qin et al found that the presence of mosaic chromosomal alterations detected in blood-derived DNA was associated with an increased risk of lung cancer among persons of Chinese and European heritage. Study Details The study involved two cohorts:...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a Chinese phase II trial (CARTIFAN-1) reported in the Journal of Clinical Oncology, Mi et al found that the anti–B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel was active in patients with relapsed or refractory multiple myeloma. Study Details...
Concurrent Olaparib and Radiotherapy for Triple-Negative Breast Cancer
In a French phase I trial reported in JAMA Oncology, Loap et al found that concurrent olaparib and radiotherapy was well tolerated in patients with triple-negative breast cancer who had incomplete pathologic response or unresectable disease after neoadjuvant chemotherapy. Survival outcomes with the ...
Cell-Free DNA Profiling in Patients With Advanced Cancers May Lead to Early Detection of Myeloid Malignancies
Researchers have found that an incidental finding of clonal hematopoiesis in liquid biopsies can be used to trigger hematologic tests to assess the risk of developing myeloid malignancies, according to a new study published by Tagliamento et al in the European Journal of Cancer. The findings were...
Sequential Dosing of Olaparib and Adavosertib in Patients With Advanced Tumors
Olaparib and adavosertib can be safely used to treat patients with cancers that are driven by certain mutations occurring in response to DNA damage if they are given in sequence rather than concurrently, according to a novel study published by Yap et al in the European Journal of Cancer. The...
Researchers Identify Specific Mutations in the BRAF Gene That May Affect Response to Treatment and Survival in Adult Brain Cancers
Researchers have identified a range of genetic mutations in gliomas that may help them understand how different mutations in the BRAF gene interact with other gene mutations—and which ones are more susceptible to targeted treatments in adults—according to a new study published by Schreck et al in...
KEYNOTE-716: Distant Metastasis–Free Survival With Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in The Lancet Oncology by Georgina V. Long, MBBS, PhD, and colleagues, an analysis from the phase III KEYNOTE-716 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival with adjuvant pembrolizumab vs placebo in resected stage IIB or IIC...
Telisotuzumab Vedotin Plus Erlotinib in c-Met Protein–Expressing NSCLC
In a phase Ib trial reported in the Journal of Clinical Oncology, D. Ross Camidge, MD, PhD, and colleagues found that the combination of telisotuzumab vedotin and erlotinib showed activity in c-Met protein–expressing advanced non–small cell lung cancer (NSCLC), including those with an EGFR mutation ...
Biomarker Assessment for Benefit of LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
In a prespecified analysis from the Australian phase II TheraP trial reported in The Lancet Oncology, Buteau et al found that higher gallium-68–labeled PSMA-11 positron-emission tomography (PSMA-PET) mean standardized uptake values (SUVmean) were associated with a greater likelihood of...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
